Revivicor's Vision
To provide organs from gene-edited pigs to overcome the critical shortage of human organs for transplant.
There is a major shortage of organs for heart and kidney transplant.
Data based on United Therapeutics internal market research, the Health Resources & Services Administration and UNOS.
Xenotransplantation is a key solution.
Pigs can provide a plentiful and accessible supply of transplantable
organs.
History
1996
Revivicor (successor to PPL Therapeutics) collaborated with the Roslin Institute to establish the world’s first cloned mammal
More Information
2000
Revivicor (successor of PPL Therapeutics) produced the world’s first cloned pigs
More Information
2001
Revivicor (successor to PPL Therapeutics) established the world’s first alpha-gal knockout pigs, the GalSafe™ lineage progenitors. The GalSafe™ line has one gene inactivated and this line is free of the epitope galactose alpha-1-3 galactose (alpha-gal)
More Information
2003
Revivicor formed as a spin-out from PPL Therapeutics
2011
Revivicor acquired by United Therapeutics Corporation to create an unlimited supply of manufactured organs for transplantation
unither.com
2020
Revivicor received a first-of-its-kind approval from the FDA for use of the GalSafe™ pig as a source of food for human consumption, and as a source of human therapeutics
Health and Safety Data FDA News Release
2021
Revivicor's UKidney™ from a pig was transplanted into the body of a recently deceased human maintained on artificial support UKidney™ is a development-stage product not approved for sale in any jurisdiction
More Information
2022
A UHeart™ from a Revivicor pig was used clinically and established a new record for longest surviving recipient of a xenotransplantation productUHeart™ is a development-stage product not approved for sale in any jurisdiction
More Information